

# Clinical Appropriateness Guidelines

# Chromosomal Microarray Analysis, Whole Exome and Whole Genome Sequencing

**EFFECTIVE MARCH 6, 2022**

**ARCHIVED SEPTEMBER 4, 2022**

This document has been archived because it has outdated information. It is for historical information only and should not be consulted for clinical use. Current versions of guidelines are available on the AIM Specialty Health website at <http://www.aimspecialtyhealth.com/>



8600 West Bryn Mawr Avenue  
South Tower - Suite 800 Chicago, IL 60631  
[www.aimspecialtyhealth.com](http://www.aimspecialtyhealth.com)

Appropriate.Safe.Affordable  
© 2022 AIM Specialty Health  
GEN07-0322.1

## Table of Contents

Scope .....	3
Genetic Counseling Requirement .....	3
Appropriate Use Criteria .....	4
Whole Exome Sequencing.....	4
Whole Exome Reanalysis.....	6
Chromosomal Microarray Analysis.....	6
Whole Genome Sequencing.....	7
CPT Codes.....	7
Background .....	9
Rationale for Genetic Counseling for WES.....	10
Whole Exome Sequencing.....	11
<i>Phenotype Suspicious of a Genetic Diagnosis</i> .....	11
<i>Whole Exome Sequencing in Developmental and Epileptic Encephalopathy</i> .....	12
<i>Whole Exome Sequencing for Sensorineural Hearing Loss</i> .....	13
<i>Whole Exome Sequencing in the Prenatal Setting</i> .....	13
Whole Exome Reanalysis.....	14
Chromosomal Microarray Analysis.....	14
Professional Society Guidelines.....	15
Selected References.....	17
Revision History.....	20

PROPRIETARY

Guidelines developed by, and used with permission from, Informed Medical Decisions, Inc. © 2015-2022 Informed Medical Decisions, Inc. All Rights Reserved.

# Scope

This document addresses the diagnostic use of chromosomal microarray analysis (CMA) and whole exome sequencing (WES) in the evaluation of rare disease. It does not address the use of WES as a technology for tumor profiling (see Clinical Appropriateness Guidelines for Molecular Testing of Solid and Hematologic Tumors and Malignancies). This document also addresses whole genome sequencing (WGS) as well as other broad scale profiling, e.g., whole transcriptome analysis and genome mapping. All tests listed in these guidelines may not require prior authorization or may have separate coverage criteria; please refer to the health plan.

## Genetic Counseling Requirement

Genetic testing, i.e., whole exome sequencing, included in these guidelines is covered when:

1. The patient meets coverage criteria outlined in the guidelines
2. A recommendation for genetic testing has been made by one of the following:
  - An independent board-certified or board-eligible medical geneticist not employed by a commercial genetic testing laboratory\*
  - An American Board of Medical Genetics or American Board of Genetic Counseling-certified genetic counselor not employed by a commercial genetic testing laboratory\*
  - A genetic nurse credentialed as either a Genetic Clinical Nurse (GCN) or an Advanced Practice Nurse in Genetics (APGN) by either the Genetic Nursing Credentialing Commission (GNCC) or the American Nurses Credentialing Center (ANCC) who is not employed by a commercial genetic testing laboratory\*

Who:

- Has evaluated the case and performed pre-test genetic counseling with the patient or the patient's legal guardian
- Has completed a three-generation pedigree
- Intends to engage in post-test follow-up counseling with the patient or the patient's legal guardian

*\*A physician, genetic counselor or genetic nurse employed by a laboratory that operates within an integrated, comprehensive healthcare delivery system is not considered to be an employee of a commercial genetic testing laboratory for the purpose of these guidelines.*

PROPRIETARY

Guidelines developed by, and used with permission from, Informed Medical Decisions, Inc. © 2015-2022 Informed Medical Decisions, Inc. All Rights Reserved.

# Appropriate Use Criteria

## Whole Exome Sequencing

Whole exome sequencing (WES) (81415 with or without 81416) is medically necessary for any of the following clinical scenarios when all of the general criteria for WES testing (below) are also met.

## Phenotype Suspicious for a Genetic Diagnosis

Testing is ordered after an individual has been evaluated by a board-certified medical geneticist or other board-certified specialist physician with specific expertise in the conditions being tested for and relevant genes, AND any of the following:

- Individual with multiple major structural or functional congenital anomalies affecting unrelated organ systems (including major metabolic disorders), OR
- Individual with one major structural or functional congenital anomaly and two or more minor structural anomalies, OR
- Individual with one major structural congenital anomaly and a family history strongly implicating a genetic etiology OR
- Individual with known or suspected developmental and epileptic encephalopathy (onset before three years of age) for which likely non-genetic causes of epilepsy (e.g., environmental exposures; brain injury secondary to complications of extreme prematurity, infection, trauma) have been excluded, OR
- Individual diagnosed with global developmental delay\* following formal assessment by a developmental pediatrician or neurologist, OR
- Individual diagnosed with moderate/severe/profound intellectual disability\*\* following formal assessment by a developmental pediatrician or neurologist, OR
- Individual with confirmed bilateral sensorineural hearing loss of unknown etiology

\*Global developmental delay is defined as significant delay in younger children, <5 years of age, in at least two of the major developmental domains: gross or fine motor; speech and language; cognition; social and personal development; and activities of daily living.

\*\*Moderate/severe/profound intellectual disability as defined by DSM-5 criteria diagnosed by 18 years of age.

## Fetal Testing

- Standard diagnostic genetic testing (chromosomal microarray analysis (CMA) and/or karyotype) of the fetus has been performed and is uninformative **AND**
- Testing is ordered in conjunction with a board-certified medical geneticist or genetic counselor **AND**

PROPRIETARY

Guidelines developed by, and used with permission from, Informed Medical Decisions, Inc. © 2015-2022 Informed Medical Decisions, Inc. All Rights Reserved.

- Testing is performed on direct amniotic fluid/chorionic villi, cultured cells from amniotic fluid/chorionic villi or DNA extracted from fetal blood or tissue **AND**
- At least one of the following is present:
  - Multiple fetal structural anomalies affecting unrelated organ systems
  - Fetal hydrops of unknown etiology
  - A fetal structural anomaly affecting a single organ system (please note exclusions below) **AND** family history strongly suggests a genetic etiology
    - Isolated anomalies excluded from coverage:
      - Isolated increased nuchal translucency
      - Isolated talipes (clubfeet)
      - Isolated neural tube defect
      - Isolated congenital heart defects
      - Isolated cleft lip and/or palate
      - Isolated congenital diaphragmatic hernia

Fetal WES is not medically necessary for any of the following indications:

- Healthy pregnancies
- Indications other than fetal structural anomalies
- Ultrasound soft markers of aneuploidy (e.g., choroid plexus cysts, echogenic bowel, intracardiac echogenic focus)

### General Criteria for WES Testing

*(All of the following criteria are necessary to pursue WES testing in the clinical scenarios above):*

- WES results will directly impact clinical decision-making and/or clinical outcome
- No other causative circumstances (e.g., environmental exposures, injury, prematurity, infection) can explain symptoms
- Clinical presentation does not fit a well-described syndrome for which single-gene or targeted panel testing is available
- The differential diagnosis list and/or phenotype warrant testing of multiple genes, and at least one of the following:
  - WES is more practical than the separate single gene tests or panels that would be recommended based on the differential diagnosis

PROPRIETARY

Guidelines developed by, and used with permission from, Informed Medical Decisions, Inc. © 2015-2022 Informed Medical Decisions, Inc. All Rights Reserved.

- WES results may preclude the need for multiple and/or invasive procedures, follow-up, or screening (“diagnostic odyssey”) that would be recommended in the absence of testing

WES is not medically necessary in the following scenarios:

- Testing using cell-free DNA
- Preimplantation testing of an embryo
- Genetic carrier screening
- Asymptomatic screening
- Oncology indications
- Isolated mild intellectual disability
- Isolated autism spectrum disorder

### **Whole Exome Reanalysis**

Reanalysis of previously obtained uninformative whole exome sequence (81417) is medically necessary when any of the following criteria is met:

- There has been onset of additional symptoms that broadens the phenotype assessed during the original exome evaluation
- There has been the birth or diagnosis of a similarly affected first-degree relative that has expanded the clinical picture
- New scientific knowledge suggests a previously unknown link between the patient’s findings and specific genes/pathogenic or likely pathogenic variants AND at least 18 months have passed since the last analysis

### **Chromosomal Microarray Analysis**

Chromosomal microarray analysis (CMA) is medically necessary for any of the following indications:

- Non-syndromic autism spectrum disorder
- Non-syndromic global developmental delay or intellectual disability\*
- Individual with multiple major structural or functional congenital anomalies affecting unrelated organ systems (including major metabolic disorders)\*
- Known or suspected developmental and epileptic encephalopathy (onset before three years of age) for which likely non-genetic causes of epilepsy (e.g., environmental exposures; brain injury secondary to complications of extreme prematurity, infection, trauma) have been excluded\*

PROPRIETARY

Guidelines developed by, and used with permission from, Informed Medical Decisions, Inc. © 2015-2022 Informed Medical Decisions, Inc. All Rights Reserved.

\*CMA is intended for use in the detection of chromosomal duplications and deletions only and is therefore indicated when the possibility of microdeletion or microduplication syndromes/conditions are suspected. It cannot detect other common variant types (e.g., sequence variants). If sequence variants are high on the differential diagnosis, please see whole exome sequencing criteria above.

For oncologic indications, please see Clinical Appropriateness Guidelines for Molecular Testing of Solid and Hematologic Tumors and Malignancies.

For reproductive indications, please see Clinical Appropriateness Guidelines for Genetic Testing for Reproductive Carrier Screening and Prenatal Diagnosis.

## Whole Genome Sequencing

Whole genome sequencing (WGS) is not medically necessary\*.

Whole genome sequencing of the transcriptome (RNA sequencing) and genome mapping are not medically necessary.

\*Please refer to the health plan for exceptions.

## CPT Codes

The following codes are associated with the guidelines outlined in this document. This list is not all inclusive. Medical plans may have additional coverage policies that supersede these guidelines.

Covered when medical necessity criteria are met:

- |       |  |
|-------|--|
| 81228 | Cytogenomic constitutional (genome-wide) microarray analysis; interrogation of genomic regions for copy number variants (eg, Bacterial Artificial Chromosome [BAC] or oligo-based comparative genomic hybridization [CGH] microarray analysis) |
| 81229 | Cytogenomic constitutional (genome-wide) microarray analysis; interrogation of genomic regions for copy number and single nucleotide polymorphism (SNP) variants for chromosomal abnormalities   |
| 81415 | Exome (eg, unexplained constitutional or heritable disorder or syndrome); sequence analysis  |
| 81416 | Exome (eg, unexplained constitutional or heritable disorder or syndrome); sequence analysis, each comparator exome (eg, parents, siblings) (List separately in addition to code for primary procedure)   |
| 81417 | Exome (eg, unexplained constitutional or heritable disorder or syndrome); re-evaluation of previously obtained exome sequence (eg, updated knowledge or unrelated condition/syndrome)  |

Codes that do not meet medical necessity criteria:

PROPRIETARY

Guidelines developed by, and used with permission from, Informed Medical Decisions, Inc. © 2015-2022 Informed Medical Decisions, Inc. All Rights Reserved.

- 81425 Genome (eg, unexplained constitutional or heritable disorder or syndrome); sequence analysis
- 81426 Genome (eg, unexplained constitutional or heritable disorder or syndrome); sequence analysis, each comparator genome (eg, parents, siblings) (List separately in addition to code for primary procedure)
- 81427 Genome (eg, unexplained constitutional or heritable disorder or syndrome); re-evaluation of previously obtained genome sequence (eg, updated knowledge or unrelated condition/syndrome)
- 0094U Genome (eg, unexplained constitutional or heritable disorder or syndrome), rapid sequence analysis
- 0209U Cytogenomic constitutional (genome-wide) analysis, interrogation of genomic regions for copy number, structural changes and areas of homozygosity for chromosomal abnormalities
- 0212U Rare diseases (constitutional/heritable disorders), whole genome and mitochondrial DNA sequence analysis, including small sequence changes, deletions, duplications, short tandem repeat gene expansions, and variants in non-uniquely mappable regions, blood or saliva, identification and categorization of genetic variants, proband (Do not report 0212U in conjunction with 81425)
- 0213U Rare diseases (constitutional/heritable disorders), whole genome and mitochondrial DNA sequence analysis, including small sequence changes, deletions, duplications, short tandem repeat gene expansions, and variants in non-uniquely mappable regions, blood or saliva, identification and categorization of genetic variants, each comparator genome (eg, parent, sibling) (Do not report 0213U in conjunction with 81426)
- 0214U Rare diseases (constitutional/heritable disorders), whole exome and mitochondrial DNA sequence analysis, including small sequence changes, deletions, duplications, short tandem repeat gene expansions, and variants in non-uniquely mappable regions, blood or saliva, identification and categorization of genetic variants, proband (Do not report 0214U in conjunction with 81415)
- 0215U Rare diseases (constitutional/heritable disorders), whole exome and mitochondrial DNA sequence analysis, including small sequence changes, deletions, duplications, short tandem repeat gene expansions, and variants in non-uniquely mappable regions, blood or saliva, identification and categorization of genetic variants, each comparator exome (eg, parent, sibling) (Do not report 0215U in conjunction with 81416)
- 0260U Rare diseases (constitutional/heritable disorders), identification of copy number variations, inversions, insertions, translocations, and other structural variants by optical genome mapping

PROPRIETARY

Guidelines developed by, and used with permission from, Informed Medical Decisions, Inc. © 2015-2022 Informed Medical Decisions, Inc. All Rights Reserved.



- 0264U Rare diseases (constitutional/heritable disorders), identification of copy number variations, inversions, insertions, translocations, and other structural variants by optical genome mapping
- 0265U Rare constitutional and other heritable disorders, whole genome and mitochondrial DNA sequence analysis, blood, frozen and formalin-fixed paraffin embedded (FFPE) tissue, saliva, buccal swabs or cell lines, identification of single nucleotide and copy number variants
- 0266U Unexplained constitutional or other heritable disorders or syndromes, tissue specific gene expression by whole transcriptome and next-generation sequencing, blood, formalin-fixed paraffin embedded (FFPE) tissue or fresh frozen tissue, reported as presence or absence of splicing or expression changes
- 0267U Rare constitutional and other heritable disorders, identification of copy number variations, inversions, insertions, translocations, and other structural variants by optical genome mapping and whole genome sequencing

CPT® (Current Procedural Terminology) is a registered trademark of the American Medical Association (AMA). CPT® five digit codes, nomenclature and other data are copyrighted by the American Medical Association. All Rights Reserved. AMA does not directly or indirectly practice medicine or dispense medical services. AMA assumes no liability for the data contained herein or not contained herein.

## Background

Whole exome sequencing (WES) is a method of analyzing the protein coding regions, also called the exome, which comprise 1-2% of the entire genome. With the ability to screen all genes, WES theoretically captures at least 85% of the genetic variants associated with human Mendelian disorders (Rabbani et al. 2014). Limitations of WES do exist and currently include reduced ability to detect copy number variants, reduced coverage depth for select genes and the potential for variants of uncertain significance and secondary findings (Zou et al. 2020; Srivastava et al. 2019). These mitigating factors have not precluded the technology from increasingly becoming a common molecular diagnostic test for individuals with suspected rare genetic disorders. WES is most appropriate when used for patients whose phenotype is strongly suggestive of a genetic disorder, but targeted testing has either been negative or is impractical due to a wide or uncertain differential diagnosis (ACMG 2012).

Several large studies have demonstrated the diagnostic utility of WES, in which diagnosis rates have ranged between 22-57% (Clark et al. 2018; Yang et al. 2014; Lee et al. 2014). Though diagnostic utility does not always directly correlate with clinical utility, providing a molecularly confirmed diagnosis can often shorten the diagnostic odyssey, improve disease management, allow for targeted treatments and surveillance for later-onset comorbidities for a subset of patients, and inform genetic counseling with respect to recurrence risks and prenatal diagnosis options for families (Sawyer et al. 2016; Malinowski et al. 2020). Even in cases for which treatments are not available, using WES to confirm a lethal diagnosis in acutely ill pediatric patients allows for the avoidance of invasive biopsies, additional workup, and appropriate implementation of palliative care (Stark et al. 2018).

PROPRIETARY

Guidelines developed by, and used with permission from, Informed Medical Decisions, Inc. © 2015-2022 Informed Medical Decisions, Inc. All Rights Reserved.

## Rationale for Genetic Counseling for WES

Pre-test genetic counseling provides individuals seeking genetic testing the opportunity to make informed decisions about their genetic testing and subsequent medical management options. Genetic counseling combines expertise in obtaining and interpreting family history information, the ability to identify the most beneficial individual in a family to initiate testing, identification of the most appropriate testing options, experience in obtaining informed consent for testing and proficiency in genetic variant interpretation, in order to maximize the genetic testing experience for patients and their healthcare providers. The genetic counseling informed consent process also educates and empowers patients to consider the psychological, financial, employment, disability, and insurance implications of genetic testing and results (Al-Khatib et al. 2018). Patients who receive genetic counseling report increased knowledge, understanding, and satisfaction regarding their genetic testing experience (Armstrong et al. 2015; Harvey et al. 2007).

The advent of multi-gene panels and genome-scale sequencing have increased the complexity of the genetic testing landscape. Misuse of genetic testing increases the risk for adverse events and patient harm, including missed opportunities for diagnosis and disease prevention (Bellcross et al. 2011; Plon et al. 2011). Genetic information requires expert interpretation and ongoing re-evaluation to ensure the most accurate interpretation is utilized to inform medical management decision making. The multitude of genetic testing options as well as the complex information revealed by genetic testing can make choosing the most appropriate test and interpretation of results difficult for non-genetics healthcare providers (Ray 2011). Involvement of a clinical genetics provider has been shown to ensure the correct test is ordered, limit result misinterpretation and allow patients to make informed, evidence-based medical decisions with their healthcare providers (Cragun et al. 2015).

Genetic counseling not only improves patient outcomes but also reduces unnecessary healthcare spending. Pre-test genetic counseling has been shown to reduce inappropriate test ordering and prevent unnecessary medical procedures and interventions that follow from inaccurate result interpretation (DHHS 2011). While genetic testing is now available for almost all clinical specialties, correct use and interpretation is necessary to prevent adverse outcomes. While genetic counseling may benefit any patient considering or undergoing genetic testing, tests that offer predictive information or have a higher chance of identifying variants of uncertain significance often carry stronger recommendations in the form of consensus guidelines and professional statements recommending genetic counseling by trained genetics professionals.

There is consensus that genetic counseling by trained genetics professionals represents best practice prior to and after ordering such tests and can identify the most appropriate tests (e.g., multi-gene panels or WES) and the most appropriate testing candidates (Yang et al. 2013).

Obtaining informed consent and providing pre-test genetic counseling by a trained genetics professional is an essential component of WES. The American College of Medical Genetics (ACMG) published specific recommendations (ACMG Board of Directors 2013):

1. Pre-test counseling should be done by a medical geneticist or an affiliated genetic counselor and should include a formal consent process
2. Prior to initiating WGS/WES, participants should be counseled regarding the expected outcomes of testing, the likelihood and type of incidental results that could be generated, and what results will or will not be disclosed

PROPRIETARY

Guidelines developed by, and used with permission from, Informed Medical Decisions, Inc. © 2015-2022 Informed Medical Decisions, Inc. All Rights Reserved.

3. As part of the pre-test counseling, a clear distinction should be made between clinical and research-based testing. In many cases, findings will include variants of unknown significance that might be the subject for research; in such instances a protocol approved by an institutional review board must be in place and appropriate prior informed consent obtained from the participant

Variants of uncertain significance and incidental or secondary findings not only complicate genetic counseling but also interpretation of WES results, and they carry a risk of harm to the patient if misinterpreted by an inexperienced clinician. Incidental or secondary findings, where variants unrelated to the clinical phenotype are identified, pose issues of informed consent but often have clear medical management recommendations (ACMG 2013; Green 2013). However, even among the list of 73 genes recommended for the reporting of secondary findings by the American College of Medical Genetics and Genomics, there are challenges in determining the phenotypic consequences of variants identified (Jurgens 2015). A study assessing clinical and psychosocial actions following receipt of secondary incidental findings revealed an overall adjusted prevalence of incidental findings in the ACMG recommended genes of 1.7% with little to no adverse impact on participants as well as only modest to near term healthcare costs (Hart et al. 2019).

## **Whole Exome Sequencing**

### ***Phenotype Suspicious of a Genetic Diagnosis***

WES is useful in diagnosing complex phenotypes. The expertise of clinical genetics specialists allows them to accurately evaluate patients and determine whether targeted testing would produce a more cost-effective and higher yield than WES. Shashi et al. (2014) retrospectively evaluated a cohort of 500 patients who received traditional medical genetics evaluations and concluded that the clinical utility of genomic testing is greater when testing is applied after an initial clinical genetics evaluation. To further this point, Baldridge, et al (2017) performed a retrospective analysis of 155 patients who underwent WES as part of their Exome Clinic. They report that after medical genetics evaluation, prior test results/clinical exam, and use of additional diagnostic modalities, their clinic's diagnostic yield was 43%. They further note that clinical management was altered in 12% of diagnosed cases.

In addition to the diagnostic power of WES, the cost-effectiveness of such testing is a compelling reason to consider its use in clinical practice. WES has been shown to reduce healthcare costs by limiting downstream medical interventions, regardless of whether a molecular diagnosis is confirmed (Vrijenhoek et al. 2018). However, WES is only cost effective if it replaces the need for multiple individual tests, and it is not as cost-effective when it is used after performing and receiving uninformative results from multiple other genetic tests. For this reason, genetics providers should consider when WES should be performed prior to more traditional testing, such as chromosomal microarray or targeted panels. Recommendations from the Clinical Genetics Think Tank, an association of American and Canadian geneticists, suggest that a targeted gene panel should be utilized if available as first-tier testing when the patient's clinical presentation is specific to a known genetic condition, and WES should only be considered as a next step if the previous panel is outdated, the patient's phenotype is atypical or has evolved, or there is clinical urgency.

### ***Whole Exome Sequencing for Global Developmental Delay (gDD)/Intellectual Disability (ID)***

PROPRIETARY

Guidelines developed by, and used with permission from, Informed Medical Decisions, Inc. © 2015-2022 Informed Medical Decisions, Inc. All Rights Reserved.

The diagnostic yield for WES has been shown in multiple studies to range from 27-50% (Anazi et al. 2017; Nolan et al. 2016). While mitigating factors such as consanguinity and difficulty separating other phenotypic features from gDD/ID is a pervasive limitation in the current evidence, the diagnostic yield has been consistently documented. Visser et al. (2017) provide supplemental data revealing a 31% diagnostic yield in 24/78 patients described with isolated intellectual disability. Kukri et al. (2019) revealed a diagnostic yield of 19% when subjects lacking reported facial dysmorphism with moderate to profound ID were analyzed.

There is evidence of utility for the use of WES in individuals with gDD/ID. Salient outcomes from whole exome sequencing considered as evidence of clinical utility include changes in management (targeted workup for systemic involvement, further disease monitoring as well as obviating the need for further testing), ending the diagnostic odyssey, and family-focused outcomes such as cascade genetic testing (Manickam et al. 2021). The ACMG performed a systematic evidence review which included a meta-analysis of 25 studies and reported a rate of change in short-term clinical management (defined as modifications to medications, procedures or treatments) of 8% (95% CI 6,11) for all patients receiving exome/genome sequencing. The Ontario Health Technology Assessment (OHTA) reported a rate of 5.9% for exome sequencing (Ontario Health Quality 2020). In a separate meta-analysis of 19 studies, the reported rate of change for long-term clinical management (defined as referral to specialists, surveillance or life-style changes) was 10% (95% CI 7, 15) with the OHTA reporting this rate of change as 17.2% (Ontario Health Quality 2020).

Clinical utility also includes reproductive-focused outcomes following WES in individuals with gDD/ID (Manickam et al. 2021; Srivastava et al. 2014; Nolan et al. 2016). When the threshold for diagnostic yield of testing is high, reproductive decision-making holds greater clinical utility; the risk for an affected child is a known factor (potentially as high as 25-50%) and not theoretical.

### ***Whole Exome Sequencing in Developmental and Epileptic Encephalopathy***

There is evidence of utility for the use of WES in individuals with early onset epilepsies. Sheidley et al. (2018) discussed possible utility of genetic testing for epilepsy includes avoidance of treatment (i.e., epilepsy surgery) and invasive diagnostic tests (lumbar puncture, muscle biopsy, frequency of brain imaging). Additionally, there are a number of specific genetic epilepsy diagnoses that lead to immediate and specific treatment recommendations. Diagnostic criteria for developmental and epileptic encephalopathy have traditionally been made based on observations on EEG, imaging, and seizure semiology. However, there is significant clinical and genetic heterogeneity in this group of conditions. Varying electroclinical syndromes are defined by ILAE and many have overlapping or heterogeneous genetic causes (Palmer et al. 2018). In this population a rapid diagnosis can significantly impact treatment options (i.e., GLUT1 deficiency of B6 dependent early onset epilepsy) or referral to other specialties or palliative care (Myers et al. 2018). Additionally, 40-50% remain undiagnosed after first tier assessment (neurological, neuroimaging, evaluation, screening for metabolic disorders, CMA and targeted genetic testing) (Palmer et al. 2018).

Vissers et al. (2017) examined 150 patients with neurological disorders (including 5 with epilepsy and 39 patients with Intellectual Disability (ID)+epilepsy or ID+movement disorder) and found that WES identified significantly more conclusive diagnoses (29.3%) than the standard care pathway (7.3%) without incurring higher costs. Nolan et al. (2016) found a diagnostic rate for WES, through a retrospective chart review, increased from 25% - 48%. Howell et al. (2018) reported an increased diagnostic yield of 67% with WES in 114 patients with severe epilepsies of infancy (SEI). Myers et al.

PROPRIETARY

Guidelines developed by, and used with permission from, Informed Medical Decisions, Inc. © 2015-2022 Informed Medical Decisions, Inc. All Rights Reserved.

(2018) compiled studies that utilized WGS and WES studies in epilepsy and encephalopathy and found that the diagnostic rate ranged from 12.5-77% for patients with various forms of early life epilepsies.

### ***Whole Exome Sequencing for Sensorineural Hearing Loss***

Approximately 80% of congenital hearing loss is due to genetic variants with roughly 20% of genetic diagnoses involving one of over 400 genetic syndromes and 80% being classified as nonsyndromic (Korver et al, 2017). Due to this heterogeneous etiology, next-generation sequencing panels are commonly used to assess large numbers of genes for diagnosis of sensorineural hearing loss (SNHL), however this approach is limited given that a majority of cases of hereditary deafness are due to rare genes and there is broad heterogeneity between families and across ethnicities. Panels differ in covered region, sequence-capturing methodology and data-analyzing pipe-line, making the sequencing results generally not compatible for cross-platform re-analysis and comparison (Zou et al. 2020).

In recent years, WES has been used to expedite identification of new genes and variants associated with hearing loss and has increased the rate of genetic diagnosis for infants with congenital hearing impairment (Downie et al. 2019; Bademci et al. 2016; Zou et al. 2020). Downie et al. (2019) reported a 56% rate of genetic diagnosis for infants with congenital bilateral hearing impairment using whole exome with clarification by microarray. In addition, the opportunity for early diagnosis of individuals who may not yet have developed syndromic features, and are too young to know if their hearing loss is stable or progressive, is significant. Confirmation of syndromic SNHL provides an opportunity for earlier screening and access to treatment and/or clinical trials. For example, individuals with Usher syndrome may have an opportunity to participate in clinical trials to prevent vision loss. Downie et al. (2019) found that (54/59) 92% of participants in their study who received a diagnosis had some change in their medical management.

Early confirmation of nonsyndromic hearing loss can also alleviate the need for additional screening. Downie et al. (2019) reports that 37/106 (36%) of infants with bilateral SNHL in their cohort were discharged from further screening and surveillance after nonsyndromic mutations were identified, reducing the burden on the family and alleviating the unnecessary utilization of healthcare resources. Stark et al. (2019) found that for the infants' families in their cohort, the major impact of early genomic diagnosis was the restoration of parental reproductive confidence. Studies are also underway to address the question of secondary findings from WES.

### ***Whole Exome Sequencing in the Prenatal Setting***

Data has demonstrated clinical utility for WES in the prenatal population after uninformative standard diagnostic testing, i.e., karyotype and/or microarray. Diagnostic yields are generally quoted as ranging from 10-57% and are dependent on associated ultrasound findings (Abou Tayoun and Mason-Suares 2019; Lord et al. 2019; Petrovski et al. 2019). Fu and colleagues (2018) reported a definitive diagnosis using WES following a normal karyotype and microarray in 22.3% of fetuses with a single malformation and 30.8% in those with multiple malformations. In addition, a high diagnostic yield (9-47%) has been reported using WES in fetuses with hydrops (Yates et al. 2017; Drury et al. 2015) providing an alternative to current commercially available panels which may not contain newly discovered pathogenic variants.

Conversely, several studies have revealed a low diagnostic yield for monogenic disorders using WES in fetuses with isolated sonographic soft markers, i.e., increased nuchal translucency, choroid plexus cysts, echogenic foci in the heart or bowel, thickened nuchal fold, absent nasal bone, single umbilical

artery, or persistent right umbilical vein (Fu et al. 2017; Lord et al. 2019; Abou Tayoun and Mason-Suares 2019). Diagnostic yield has also been determined to be proportional to the severity of the ultrasound findings, i.e., higher for fetuses with more than two anomalies (Monaghan et al. 2020; Lord et al. 2019). There is also concern about difficulties in interpreting WES results for isolated findings such as complex cardiac defects (Pasipoularides 2018). Therefore, when pursuing testing for isolated congenital anomalies it should only be considered in those with demonstrated informative results and high diagnostic yield.

The American College of Medical Genetics (ACMG) has recently published considerations for the use of WES in the prenatal setting (Monaghan et al. 2020). While ACMG has suggested consideration of WES for fetuses likely to have a genetic disorder when other investigations have not yielded a diagnosis, it is important to remain cognizant of the limitations in the prenatal setting. Identification of fetal structural anomalies using ultrasonography limits the ability for clinicians to ascertain the full phenotypic spectrum which may impact the interpretation of WES (Aarabi et al. 2018). The relatively long turnaround time of WES has historically been a limitation for its use in a prenatal setting, especially when ultrasound findings are not detected until later gestational ages (Daum et al. 2019). However, emerging technologies allow for more rapid completion of test results (Felice et al. 2019). Prenatal WES may also be considered in the context of research in cases that do not meet clinical criteria for testing.

## Whole Exome Reanalysis

There may be scenarios in which reanalysis of previously uninformative whole exome sequence data is medically necessary. This includes the onset of additional symptoms that broaden the phenotype assessed during the original exome evaluation, or the birth or diagnosis of a similarly affected first-degree relative that has expanded the clinical picture. In addition, due to the rapid increase in knowledge surrounding disease genes and phenotypes, WES reanalysis can be helpful at future time intervals. Reanalysis of exome data has shown to increase the diagnostic yield by 11-16% when performed one to three years after initial testing (Alfares et al. 2018; Ewans et al. 2018; Hiatt et al. 2018). Reanalysis can also help re-classify previously detected variants of uncertain significance.

## Chromosomal Microarray Analysis

Chromosomal microarray (CMA) or comparative genomic hybridization (CGH) detects microduplications and microdeletions of chromosomal DNA. Many studies have validated this technology as a more sensitive alternative to traditional cytogenetic karyotyping. CMA is now recommended as a first-tier test in place of karyotyping for multiple indications, although the technology cannot detect balanced rearrangements (e.g., balanced reciprocal translocations). SNP arrays are a specific type of oligonucleotide array that targets alternative alleles at SNPs within the genome. SNP array offers the ability to analyze a sample at a higher resolution than metaphase cytogenetics for DNA copy number alterations (duplications and deletions), copy number polymorphisms, and loss of heterozygosity (LOH).

The ACMG recommends CMA as a first-tier test in the initial postnatal evaluation of individuals with multiple anomalies not specific to a well-delineated genetic syndrome, apparently non-syndromic developmental delay/intellectual disability, and autism spectrum disorders (Manning et al. 2020; Shao et al. 2021).

In addition, if a specific syndrome is not readily identified, then chromosomal microarray would be a reasonable first line diagnostic measure for those with developmental and epileptic encephalopathies.

PROPRIETARY

Guidelines developed by, and used with permission from, Informed Medical Decisions, Inc. © 2015-2022 Informed Medical Decisions, Inc. All Rights Reserved.

Chromosomal microarray has been found to have diagnostic yields in the approximately 5–30% range in various studies in epilepsy (Noh et al. 2012). Specific to epileptic encephalopathies, array comparative hybridization (aCGH) has been reported to identify copy number variants in ~4-13% with further confirmed de novo and pathogenic variants in 2.9-13% (Epilepsy Phenome/Genome Project & Epi4K Consortium 2015; Mercimek-Mahmutoglu et al. 2015). Another study found that in patients presenting with early life epilepsies 32/188 (17%) had diagnostic/pathogenic findings on CMA (Berg et al. 2017). Other groups have found similar yields (Allen et al. 2015; Poduri 2017; Mefford et al. 2011; Olson et al. 2014; Tumiene et al. 2018). This rate is similar to diagnostic rates for autism spectrum disorders as noted by ACMG (Schaefer and Mendelsohn 2013).

See the Reproductive Carrier Screening and Prenatal Diagnosis Guideline for use of microarray in the reproductive setting.

### **Evaluation of Regions of Homozygosity (ROH)**

In addition to identifying copy number variants, SNP arrays can identify areas of the genome with allelic homozygosity. These regions of homozygosity are identified in approximately 6% of individuals undergoing SNP array for clinical reasons (Wang et al. 2015). Most of these are caused by consanguinity, others are caused by uniparental disomy or ancestral homozygosity. With ROH, there is a concern for pathology caused by imprinting, such as Angelman or Prader Willi syndromes, or for recessive conditions as there is a higher likelihood of having homozygous P/LP variants in genes found within the ROH. No guidelines exist for how to approach further evaluation of ROH after they have been identified. If the ROH is found within a region known to be imprinted, UPD studies should be considered. To evaluate for recessive conditions, the preferred approach would be to search genes in the region associated with disease and identify candidate genes based on clinical symptoms. Sequencing of the entire region may be considered in select cases if no candidate gene is identified, but increases the chance of identifying a variant of uncertain significance or P/LP variants in genes that are not clinically actionable.

### **Understanding the Clinical Relevance of Copy Number Variants**

Inter-laboratory interpretation of copy number variants across technologies, e.g., CMA or NGS platforms, is complex and evolving but must be consistent. The American College of Medical Genetics and Genomics (ACMG) and the Clinical Genome Resource (ClinGen) recommend a uniform five-tier CNV variant classification system outlined in the ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015; Riggs et al. 2020). Utilizing evidence at a given point in time supporting or refuting a particular variant's pathogenicity, regardless of patient-specific factors, will produce necessary consistency and clarity in establishing potential clinical impact (Riggs et al. 2020).

## **Professional Society Guidelines**

### **American College of Medical Genetics and Genomics (ACMG)**

ACMG Clinical Practice Resource. Array-Based Technology and Recommendations for Utilization in Medical Genetics Practice for Detection of Chromosomal Abnormalities.

*Manning M, Hudgins L. 2020 Dec;22(12):2126. PubMed PMID: 32514088.*

ACMG Clinical Guideline. Exome and Genome Sequencing for Pediatric Patients with Congenital Anomalies or Intellectual Disability.

PROPRIETARY

Guidelines developed by, and used with permission from, Informed Medical Decisions, Inc. © 2015-2022 Informed Medical Decisions, Inc. All Rights Reserved.

Manickam K, McClain MR, Demmer LA, et al.; ACMG Board of Directors. *Genet Med.* 2021 Jul 1. PubMed PMID: 34211152.

ACMG Points to Consider Statement. DNA-Based Screening and Population Health. Murray M, Giovanni M, Doyle D, et al. *Genet Med.* 2021 Jun;23(6):989-995. PubMed PMID: 33727704.

ACMG Practice Guidelines. Clinical Genetics Evaluation in Identifying the Etiology of Autism Spectrum Disorders. Schaefer GB, Mendelsohn NJ. *Genet Med.* 2013 May;15(5):399-407. PubMed PMID: 23519317.

ACMG Statement. The Use of Fetal Exome Sequencing in Prenatal Diagnosis: A Points to Consider Document. Monaghan KG, Leach NT, Pekarek D, Prasad P, Rose NC, ACMG Professional Practice and Guidelines Committee. *Genet Med.* 2020 Apr;22(4):675-680. PubMed PMID: 31911674.

ACMG Statement. Recommendations for Reporting of Secondary Findings in Clinical Exome and Genome Sequencing, 2021 Update. Miller D, Lee K, Gordon A, et al. *Genetic Med.* 2021 Aug;23(8):1391-1398. PubMed PMID: 34012069.

ACMG Statement. Points to Consider in the Clinical Application of Genomic Sequencing. ACMG Board of Directors. *Genet Med.* 2012 Aug;14(8):759-61. PubMed PMID: 22863877.

ACMG Statement. Points to Consider for Informed Consent for Genome/Exome Sequencing. ACMG Board of Directors. *Genet Med.* 2013 Sep;15(9):748-9. PubMed PMID: 23970068.

ACMG Statement. Pediatric Clinical Exome/Genome Sequencing and the Engagement Process: Encouraging Active Conversation with the Older Child and Adolescent: Points to Consider. Bush, L.W., Bartoshesky, L.E., David, K.L. et al. *Genet Med* 2018 Jul;20(7):692-694. PubMed PMID: 29565417.

ACMG Technical Standard. Chromosomal Microarray Analysis, Including Constitutional and Neoplastic Disease Applications, 2021 revision. Shao L, Akkari Y, Cooley L, et al. *Genet Med.* 2021 June 15. PubMed PMID: 34131312.

ACMG Technical Standard. Next-Generation Sequencing for Constitutional Variants in the Clinical Laboratory, 2021 revision. Rehder C, Bean LJH, Bick D, et al. *Genet Med.* 2021 Apr 29. PubMed PMID: 33927380.

### **Association for Molecular Pathology (AMP)**

The Spectrum of Clinical Utilities in Molecular Pathology Testing Procedures for Inherited Conditions and Cancer.

Joseph L, Cankovic M, Caughron S, et al. *J Mol Diagn.* 2016 Sep;18(5):605-19. PubMed PMID: 27542512.

### **American College of Obstetricians and Gynecologists (ACOG)**

ACOG Committee Opinion No. 682. Microarrays and Next-Generation Sequencing Technology: The Use of Advanced Genetic Diagnostic Tools in Obstetrics and Gynecology.

*Obstet Gynecol.* 2016 Dec [reaffirmed 2020];128(6):e262-8. PubMed PMID: 27875474.

## **Joint Statements**

PROPRIETARY

Guidelines developed by, and used with permission from, Informed Medical Decisions, Inc. © 2015-2022 Informed Medical Decisions, Inc. All Rights Reserved.



Standards and Guidelines for the Interpretation of Sequence Variants. ACMG and Association for Molecular Pathology (AMP). Joint Consensus Recommendation.

Richards S, Aziz N, Bale S, et al.; ACMG Laboratory Quality Assurance Committee. *Genet Med*. 2015 May;17(5):405-424. PubMed PMID: 25741868.

Technical Standards for the Interpretation and Reporting of Constitutional Copy-Number Variants. ACMG and Clinical Genome Resource (ClinGen).

Riggs ER, Andersen EF, Cherry AM, et al.; ACMG. *Genet Med*. 2020 Feb;22(2):245-257. PubMed PMID: 31690835.

The Use of Genome-Wide Sequencing for Fetal Diagnosis. Joint Position Statement from the International Society for Prenatal Diagnosis, Society for Maternal and Fetal Medicine, Perinatal Quality Foundation.

*Prenat Diagn*. 2018; 38(1): 6-9. PubMed PMID: 29315690.

## Selected References

- 1 Aarabi M, Sniezek O, Jiang H, Saller DN, Bellissimo D, Yatsenko SA, Rajkovic A. Importance of complete phenotyping in prenatal whole exome sequencing. *Hum Genet*. 2018 Feb;137(2):175-181. PubMed PMID: 29392406.
- 2 Abou Tayoun A, Mason-Suares H. Considerations for whole exome sequencing unique to prenatal care. *Hum Genet*. 2019 Nov 7. [Epub ahead of print] PubMed PMID: 31701237.
- 3 Adhikari AN, Gallagher RC, Wang Y, Currier RJ, Amatuni G, Bassaganyas L, Chen F, Kundu K, Kvale M, Mooney SD, Nussbaum RL, Randi SS, Sanford J, Shieh JT, Srinivasan R, Sunderam U, Tang H, Vaka D, Zou Y, Koenig BA, Kwok PY, Risch N, Puck JM, Brenner SE. The role of exome sequencing in newborn screening for inborn errors of metabolism. *Nat Med*. 2020 Aug 10. Epub ahead of print. PMID: 32778825.
- 4 Alfares A, Aloraini T, Subaie LA, et al. Whole-genome sequencing offers additional but limited clinical utility compared with reanalysis of whole-exome sequencing. *Genet Med*. 2018 Nov;20(11):1328-1333. PubMed PMID: 29565419.
- 5 Allen NM, Conroy J, Shahwan A, et al. Chromosomal microarray in unexplained severe early onset epilepsy - A single centre cohort. *Eur J Paediatr Neurol*. 2015 Jul;19(4):390-4. Epub 2015 Apr 10. PubMed PMID: 25920948.
- 6 Amendola LM, Jarvik GP, Leo MC, et al. Performance of ACMG-AMP Variant-Interpretation Guidelines among nine laboratories in the Clinical Sequencing Exploratory Research Consortium. *Am J Hum Genet*. 2016 Jun 2;98(6):1067-76. Epub 2016 May 12. PubMed PMID: 27181684.
- 7 Anazi, S. et al. Clinical genomics expands the morbid genome of intellectual disability and offers a high diagnostic yield. *Mol. Psychiatry*. 22, 615–624 (2017). PubMed PMID: 27431290.
- 8 Auer PL, Reiner AP, Wang G, et al. Guidelines for large-scale sequence-based complex trait association studies: lessons learned from the NHLBI Exome Sequencing Project. *Am J Hum Genet*. 2016 Oct 6;99(4):791-801. Epub 2016 Ep 22. PubMed PMID: 27666372.
- 9 Bademci G, Foster J 2nd, Mahdieh N, et al. Comprehensive analysis via exome sequencing uncovers genetic etiology in autosomal recessive nonsyndromic deafness in a large multiethnic cohort. *Genet Med*. 2016 Apr;18(4):364-71. PMID: 26226137.
- 10 Baris HN, Tan W-H, Kimonis VE, et al. Diagnostic utility of array-based comparative genomic hybridization in a clinical setting. *Am J Med Genet Part A* 2007;143A:2523-33. PubMed PMID: 17910064.
- 11 Beaudet AL. The utility of chromosomal microarray analysis in developmental and behavioral pediatrics. *Child Dev*. 2013 Jan-Feb;84(1):121-32. Epub 2013 Jan 11. PubMed PMID: 23311723.
- 12 Bélanger SA, Caron J. Evaluation of the child with global developmental delay and intellectual disability. *Paediatr Child Health*. 2018 Sep;23(6):403-419. PMID: 30919832.
- 13 Berg AT, Coryell J, Saneto RP, et al. Early-life epilepsies and the emerging role of genetic testing. *JAMA Pediatr*. 2017 Sep 1;171(9):863-71. PubMed PMID: 28759667.
- 14 Best S, Wou K, Vora N, et al. Promises, pitfalls and practicalities of prenatal whole exome sequencing. *Prenat Diagn*. 2018 Jan;38(1):10-19. Epub 2017 Jul 25. PubMed PMID: 28654730.
- 15 Biesecker LG, Green RC. Diagnostic clinical genome and exome sequencing. *N Engl J Med*. 2014 Jun 19;370(25):2418-25. Review. PubMed PMID: 24941179.
- 16 Chang YS, Huang HD, Yeh KT, et al. Evaluation of whole exome sequencing by targeted gene sequencing and Sanger sequencing. *Clin Chim Acta*. 2017 Jun 15; 471:222-32. Epub 2017 Jun 15. PubMed PMID: 28624499.
- 17 Costain G, Jobling R, Walker S, et al. Periodic reanalysis of whole-genome sequencing data enhances the diagnostic advantage over standard clinical genetic testing. *Eur J Hum Genet*. 2018 Feb 16; May;26(5):740-744. Epub 2018 Feb 16. PubMed PMID: 29453418.

PROPRIETARY

Guidelines developed by, and used with permission from, Informed Medical Decisions, Inc. © 2015-2022 Informed Medical Decisions, Inc. All Rights Reserved.

- 18 Donley G, Hull SC, Berkman BE. Prenatal whole genome sequencing: just because we can, should we? *Hastings Cent Rep.* 2012 Jul-Aug;42(4):28-40. Epub 2012 Jun 20. PubMed PMID: 22777977.
- 19 Downie L, Halliday J, Burt R, et al. Exome sequencing in infants with congenital hearing impairment: a population-based cohort study. *Eur J Hum Genet.* 2019 Dec 12. Epub ahead of print. PMID: 31827275.
- 20 Downie L, Halliday J, Lewis S, et al. Exome sequencing in newborns with congenital deafness as a model for genomic newborn screening: The Baby Beyond Hearing project. *Genet Med.* 2020 Jan 24. Epub ahead of print. PMID: 31974413.
- 21 Downie L, Amor DJ, Halliday J, Lewis S, Martyn M, Goranitis I. Exome Sequencing for Isolated Congenital Hearing Loss: A Cost-Effectiveness Analysis. *Laryngoscope.* 2020 Dec 31. PubMed PMID: 33382469.
- 22 Drury S, Williams H, Trump N, Boustred C, GOSGene, Lench N, Scott RH, Chitty LS. Exome sequencing for prenatal diagnosis of fetuses with sonographic abnormalities. *Prenat Diagn.* 2015 Oct;35(1):1010-1017. PubMed PMID: 26275891.
- 23 Du C, Pusey BN, Adams CJ, et al. Explorations to improve the completeness of exome sequencing. *BMC Med Genomics.* 2016 Aug 27;9(1):56. PubMed PMID: 27568008.
- 24 Duam H, Meiner V, Elpeleg O, Harel T, collaborating authors. Fetal exome sequencing: yield and limitations in a tertiary referral center. *Ultrasound Obstet Gynecol.* 2019 Jan;53(1):80-86. PubMed PMID: 29947050.
- 25 Ellison JW, Ravnan JB, Rosenfeld JA, et al. Clinical utility of chromosomal microarray analysis. *Pediatrics.* 2012 Nov;130(5): e1085-95. Epub 2012 Oct 15. PubMed PMID: 23071206.
- 26 Epilepsy Phenome/Genome Project Epi4K Consortium. Copy number variant analysis from exome data in 349 patients with epileptic encephalopathy. *Ann Neurol.* 2015 Aug;78(2):323-8. Epub 2015 Jul 1. PubMed PMID: 26068938.
- 27 Ewans LJ, Schofield D, Shrestha R, et al. Whole-exome sequencing reanalysis at 12 months boosts diagnosis and is cost-effective when applied early in Mendelian disorders. *Genet Med.* 2018 Dec;20(12):1564-1574. PubMed PMID: 29595814.
- 28 Felice V, Abhyankar A, Jobanputra V. Prenatal diagnosis by whole exome sequencing in fetuses with ultrasound abnormalities. *Methods Mol Biol.* 2019; 1885:267-285. PubMed PMID: 30506204.
- 29 Fu F, Li R, Li Y, Nie ZQ, Lei T, Wang D, et al. Whole exome sequencing as a diagnostic adjunct to clinical testing in fetuses with structural abnormalities. *Ultrasound Obstet Gynecol.* 2018 Apr;51(4):483-502. PubMed PMID: 28976722.
- 30 Goldfeder RL, Priest JR, Zook JM, et al. Medical implications of technical accuracy in genome sequencing. *Genome Med.* 2016 Mar 2;8(1):24. PubMed PMID: 26932475.
- 31 Green RC, Goddard KA, Jarvik GP, et al. Clinical Sequencing Exploratory Research Consortium: accelerating evidence-based practice of genomic medicine. *Am J Hum Genet.* 2016 Jun 2;98(6):1051-66. Epub 2016 May 12. PubMed PMID: 27181682.
- 32 Hart MR, Biesecker BB, Blout CL, Christensen KD, Amendola LM, Bergstrom KL, et al. Secondary findings from clinical genomic sequencing: prevalence, patient perspectives, family history assessment, and health-care costs from a multisite study. *Genet Med.* 2019 May;21(5):1100-1110. PubMed PMID: 30287922.
- 33 Hiatt SM, Amaral MD, Bowling KM, et al. Systematic reanalysis of genomic data improves quality of variant interpretation. *Clin Genet.* 2018 Jul;94(1):174-178. PubMed PMID: 29652076.
- 34 Hiraide T, Yamoto K, Masunaga Y, et al. Genetic and phenotypic analysis of 101 patients with developmental delay or intellectual disability using whole-exome sequencing. *Clin Genet.* 2021 Jul;100(1):40-50. PMID: 33644862.
- 35 Hollenbeck D, Williams CL, Drazba K, et al. Clinical relevance of small copy-number variants in chromosomal microarray clinical testing. *Genet Med.* 2017 Apr;19(4):377-85. Epub 2016 Sep 15. PubMed PMID: 27632688.
- 36 Howell KB, Eggers S, Dalziel K, et al. A population-based cost-effectiveness study of early genetic testing in severe epilepsies of infancy. *Epilepsia.* 2018 Jun;59(6):1177-87. Epub 2018 May 11. PubMed PMID: 29750358.
- 37 Johansen Taber KA, Dickinson BD, Wilson M. The promise and challenges of next-generation genome sequencing for clinical care. *JAMA Intern Med.* 2014 Feb 1;174(2):275-80. PubMed PMID: 24217348.
- 38 Jurgens J, Ling H, Hetrick K, et al. Assessment of incidental findings in 232 whole-exome sequences from the Baylor-Hopkins Center for Mendelian Genomics. *Genet Med.* 2015 Oct;17(10):782-8. Epub 2015 Jan 8. PubMed PMID: 25569433.
- 39 Korver AM, Smith RJ, Van Camp G, et al. Congenital hearing loss. *Nat Rev Dis Primers.* 2017 Jan 12; 3:16094. PMID: 28079113.
- 40 Kremer LS, Bader DM, Mertes C, et al. Genetic diagnosis of Mendelian disorders via RNA sequencing. *Nat Commun.* 2017 Jun 12; 8:15824. PubMed PMID: 28604674.
- 41 Kurian AW, Hare EE, Mills MA, et al. Clinical evaluation of a multiple-gene sequencing panel for hereditary cancer risk assessment. *J Clin Oncol.* 2014 Jul 1;32(19):2001-9. Epub 2014 Apr 14. PubMed PMID: 24733792.
- 42 Kurki MI, Saarentaus E, Pietiläinen O, Gormley P, et al. Contribution of rare and common variants to intellectual disability in a sub-isolate of Northern Finland. *Nat Commun.* 2019 Jan 24;10(1):410. PubMed PMID: 30679432.
- 43 Lord J, McMullan DJ, Eberhardt RY, Rinck G, Hamilton SJ, Quinlan-Jones E, et al. Prenatal exome sequencing analysis in fetal structural anomalies detected by ultrasonography (PAGE): a cohort study. *Lancet.* 2019 Feb 23;393(10173):747-757. PubMed PMID: 30712880.
- 44 Malinowski J, Miller DT, Gannon J, Pereira EM, Schroeder MC, Scheuner MT, et al. Systematic evidence-based review: outcomes from exome and genome sequencing for pediatric patients with congenital anomalies or intellectual disability. *Genet Med.* 2020 Mar 23. PubMed PMID: 32203227.
- 45 Mefford HC, Yendle SC, Hsu C, et al. Rare copy number variants are an important cause of epileptic encephalopathies. *Ann Neurol.* 2011 Dec;70(6):974-85. PubMed PMID: 22190369.
- 46 Mercimek-Mahmutoglu S, Patel J, Cordeiro D, et al. Diagnostic yield of genetic testing in epileptic encephalopathy in childhood. *Epilepsia.* 2015 May;56(5):707-16. Epub 2015 Mar 25. PubMed PMID: 25818041.

PROPRIETARY

Guidelines developed by, and used with permission from, Informed Medical Decisions, Inc. © 2015-2022 Informed Medical Decisions, Inc. All Rights Reserved.

- 47 Michelucci et al., Genetics of epilepsy and relevance to current practice. *Current Neurology and Neuroscience Reports*, August 2012, Volume 12, Issue 4, pp 445-55. PubMed PMID: 22618127.
- 48 Miller DT, Adam MP, Aradhya S, et al. Chromosomal Microarray is a First-Tier Clinical Diagnostic Test for Individuals with Developmental Disabilities or Congenital Anomalies. *Am J Hum Genet*. 2010 May 14;86(5):749-64. PubMed PMID: 20466091.
- 49 Miller DT, Lee K, Chung WK, et al.; ACMG Secondary Findings Working Group. ACMG SF v3.0 list for reporting of secondary findings in clinical exome and genome sequencing: a policy statement of the American College of Medical Genetics and Genomics (ACMG). *Genet Med*. 2021 May 20. PubMed PMID: 34012068.
- 50 Miller DT, Lee K, Gordon AS, et al.; ACMG Secondary Findings Working Group. Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2021 update: a policy statement of the American College of Medical Genetics and Genomics (ACMG). *Genet Med*. 2021 May 20. PubMed PMID: 34012069.
- 51 Myers KA, Johnstone DL, Dyment DA. Epilepsy genetics: Current knowledge, applications, and future directions. *Clin Genet*. 2018 Jul 10. doi: 10.1111/cge.13414. [Epub ahead of print] Review. PubMed PMID: 29992546.
- 52 Noh GJ, Jane Tavyev Asher Y, Graham JM Jr. Clinical review of genetic epileptic encephalopathies. *Eur J Med Genet*. 2012 May;55(5):281-98. Epub 2012 Jan 25. PubMed PMID: 22342633.
- 53 Nolan, D. & Carlson, M. Whole exome sequencing in pediatric neurology patients: clinical implications and estimated cost analysis. *J Child Neurol*. 2016 Jun;31(7):887-94. PubMed PMID: 26863999.
- 54 Nolan D, Fink J. Genetics of epilepsy. *Handb Clin Neurol*. 2018; 148:467-91. PubMed PMID: 29992546.
- 55 Olson H, Shen Y, Avallone J, et al. Copy number variation plays an important role in clinical epilepsy. *Ann Neurol*. 2014 Jun;75(6):943-58. Epub 2014 Jun 13. PubMed PMID: 24811917.
- 56 Ontario Health (Quality). Genome-Wide Sequencing for Unexplained Developmental Disabilities or Multiple Congenital Anomalies: A Health Technology Assessment. *Ont Health Technol Assess Ser*. 2020 Mar 6;20(11):1-178. PubMed PMID: 32194879.
- 57 Palmer EE, Schofield D, Shrestha R, et al. Integrating exome sequencing into a diagnostic pathway for epileptic encephalopathy: Evidence of clinical utility and cost effectiveness. *Mol Genet Genomic Med*. 2018 Mar;6(2):186-99. Epub 2018 Jan 4. PubMed PMID: 29314763.
- 58 Pasipoularides A. the new era of whole-exome sequencing in congenital heart disease: brand-new insights into rare pathogenic variants. *J Thorac Dis*. 2018 Jun; 10(Suppl 17): S1923-S1929. PubMed PMID: 30023082.
- 59 Petrovski S, Aggarwal V, Giordano JL, Stosic M, Wou K, Bier L, et al. Whole-exome sequencing in the evaluation of fetal structural anomalies: a prospective cohort study. *Lancet*. 2019 Feb 23;393(10173):758-767. PubMed PMID: 30712878.
- 60 Poduri A. When should genetic testing be performed in epilepsy patients? *Epilepsy Curr*. 2017 Jan-Feb;17(1):16-22. PubMed PMID: 28331464.
- 61 Rabbani B, Tekin M, Mahdieh N. The promise of whole-exome sequencing in medical genetics. *J Hum Genet*. 2014 Jan;59(1):5-15. PMID: 24196381.
- 62 Shashi V, McConkie-Rosell A, Rosell B, et al. The utility of the traditional medical genetics diagnostic evaluation in the context of next-generation sequencing for undiagnosed genetic disorders. *Genet Med*. 2014 Feb;16(2):176-82. Epub 2013 Aug 29. PubMed PMID: 23928913.
- 63 Sheidley BR, Smith LA, and KL Helbig, et al. Genetics of epilepsy in the era of precision medicine: implications for testing, treatment, and genetic counseling. *Curr Genet Med Rep*. 2018; 6(2): 73-8. <https://doi.org/10.1007/s40142-018-0139-8>.
- 64 South St, Lee C, Lamb AN, et al; Working Group for the American College of Medical Genetics and Genomics Laboratory Quality Assurance Committee. ACMG Standards and Guidelines for constitutional cytogenomic microarray analysis including postnatal and prenatal applications: revision 2013. *Genet Med*. 2013 Nov;15(11):901-9. PubMed PMID: 24071783.
- 65 Srivastava, S. et al. Clinical whole exome sequencing in child neurology practice. *Ann. Neurol*. 76, 473–483 (2014). PubMed PMID: 25131622.
- 66 Stark Z, Schofield D, Martyn M, et al. Correction: Does genomic sequencing early in the diagnostic trajectory make a difference? A follow-up study of clinical outcomes and cost-effectiveness. *Genet Med*. 2019 Feb;21(2):516. Erratum for: *Genet Med*. 2019 Jan;21(1):173-180. PMID: 30158691.
- 67 Sys M, Van den Bogaert A, Roosens B, et al. Can clinical characteristics be criteria to perform chromosomal microarray-analysis in children and adolescents with autism spectrum disorders? *Minerva Pediatr*. 2018 Jun;70(3):225-232. Epub 2016 Sep 8. PubMed PMID: 27607483.
- 68 Toluoso LK, Hazelton P, Wong B, Swarr DT. Beyond diagnostic yield: prenatal exome sequencing results in maternal, neonatal, and familial clinical management changes. *Genet Med*. 2021 Jan 13:1–9. PubMed PMID: 33442022.
- 69 Tumiené B, Maver A, Writzl K, Hodžić A, Čuturilo G, Kuzmanić-Šamija R, Čulić V, Peterlin B. Diagnostic exome sequencing of syndromic epilepsy patients in clinical practice. *Clin Genet*. 2018 May;93(5):1057-62. Epub 2018 Mar 23. PubMed PMID: 29286531.
- 70 Van El CG, Cornel MC, Borry P, et al. Whole-genome sequencing in health care: recommendations of the European Society of Human Genetics. *Eur J Hum Genet*. 2013 Jun;21(6):580-4. PubMed PMID: 23676617.
- 71 Vassy JL, Christensen KD, Schonman EF, et al. The impact of whole-genome sequencing on the primary care and outcomes of healthy adult patients: A pilot randomized trial. *Ann Intern Med*. 2017;167(3):159-69. PubMed PMID: 28654958.
- 72 Vissers LELM, van Nimwegen KJM, Schieving JH, et al. A clinical utility study of exome sequencing versus conventional genetic testing in pediatric neurology. *Genet Med*. 2017 Sep;19(9):1055-63. Epub 2017 Mar 23. PubMed PMID: 28333917.
- 73 Wang JC, Ross L, Mahon LW, et al. Regions of homozygosity identified by oligonucleotide SNP arrays: evaluating the incidence and clinical utility. *Eur J Hum Genet*. 2015 May;23(5):663-71. Epub 2014 Aug 13. PubMed PMID 25118026.
- 74 Weber YG, Biskup S, Helbig KL, et al. The role of genetic testing in epilepsy diagnosis and management. *Expert Rev Mol Diagn*. 2017 Aug;17(8):739-50. Epub 2017 Jun 26. PubMed PMID: 28548558.
- 75 Wenger AM, Guturu H, Bernstein JA, et al. Systematic reanalysis of clinical exome data yields additional diagnoses: implications for providers. *Genet Med*. 2017 Feb;19(2):209-14. Epub 2016 Jul 21. PubMed PMID: 27441994.
- 76 Winand R, Hens K, Dondorp W, et al. In vitro screening of embryos by whole-genome sequencing: now, in the future or never? *Hum Reprod*. 2014 Apr;29(4):842-51. Epub 2014 Feb 2. PubMed PMID: 24491297.

PROPRIETARY

Guidelines developed by, and used with permission from, Informed Medical Decisions, Inc. © 2015-2022 Informed Medical Decisions, Inc. All Rights Reserved.

- 77 Wright CF, McRae JF, Clayton S, et al. Making new genetic diagnoses with old data: iterative reanalysis and reporting from genome-wide data in 1,133 families with developmental disorders. *Genet Med*. 2018 Jan 11. PubMed PMID: 29323667
- 78 Yang Y, Muzny DM, Reid JG, et al. Clinical whole-exome sequencing for the diagnosis of Mendelian disorders. *N Engl J Med*. 2013 Oct 17;369(16):1502-11. Epub 2013 Oct 2. PubMed PMID: 24088041.
- 79 Yates CL, Monaghan KG, Copenheaver D, Retterer K, Scuffins J, Kucera CR, et al. Whole-exome sequencing on deceased fetuses with ultrasound anomalies: expanding our knowledge of genetic disease during fetal development. *Genet Med*. 2017 Oct;19(10): 1171-1178. PubMed PMID: 28425981.
- 80 Zawati MH, Parry D, Thorogood A, et al. Reporting results from whole-genome and whole-exome sequencing in clinical practice: a proposal for Canada? *J Med Genet*. 2014 Jan;51(1):68-70. Epub 2013 Sep 27. PubMed PMID: 24078715.
- 81 Zou S, Mei X, Yang W, et al. Whole-exome sequencing identifies rare pathogenic and candidate variants in sporadic Chinese Han deaf patients. *Clin Genet*. 2020 Feb;97(2):352-356. PMID: 31486067.

# Revision History

## Medical Advisory Board Review:

- v1.2022 09/20/2021: Approved
- v2.2021 03/12/2021: Approved
- v1.2021 11/13/2020: Approved
- v2.2020 05/08/2020: Reviewed
- v1.2020 11/04/2019: Reviewed
- v2.2019 05/23/2019: No Criteria Changes
- v1.2019 11/07/2018: Reviewed
- v1.2018 03/31/2018: Reviewed

## Clinical Steering Committee Review:

- v1.2022 08/23/2021: Approved
- v2.2021 02/22/2021: Approved
- v1.2021 10/13/2020: Approved
- v2.2020 04/06/2020: Approved
- v1/2020 10/11/2019: Approved
- v2.2019 04/03/2019: Approved
- v1.2019 10/03/2018: Approved

PROPRIETARY

Guidelines developed by, and used with permission from, Informed Medical Decisions, Inc. © 2015-2022 Informed Medical Decisions, Inc. All Rights Reserved.

v1.2018 02/28/2018: Approved

v1.2017 01/25/2017: Approved

**Revisions:**

Version	Date	Editor	Description
v1.2022 GEN07-0322.1	08/16/2021	Carrie Langbo, MS, CGC, Heather Dorsey, MS, CGC and Amanda Archbold, MS, CGC	Semi-annual update. CMA criteria and content incorporated with no changes in coverage stance. WES criteria updated to include testing for gDD and moderate/severe/profound ID. WES not medically necessary list was updated. The background, professional society guidelines, CPT codes and references were updated.
v2.2021 GEN07-0921.1	02/15/2021	Carrie Langbo, MS, CGC	Semi-annual update. Neurological features for WES criteria were clarified and epilepsy criteria was updated to reflect new terminology for developmental and epileptic encephalopathies. The background, professional society guidelines and references were updated.
v1.2021	9/11/2020	Heather Dorsey, MS, CGC	Semi-annual update. Genetic counseling requirements were updated as well as criteria across WES testing for phenotype suspicious of a genetic disorder, epilepsy, hearing loss and reanalysis. CPT codes, professional society guidelines and the background were updated.
v2.2020	03/13/2020	Carrie Langbo, MS, CGC	Whole exome sequencing criteria was updated to include coverage criteria for fetal testing, and individuals with hearing loss. CPT codes, professional society guidelines, background and references were updated.

PROPRIETARY

Guidelines developed by, and used with permission from, Informed Medical Decisions, Inc. © 2015-2022 Informed Medical Decisions, Inc. All Rights Reserved.

v1.2020	9/11/2019	Samantha Freeze, MS, CGC	Semi-annual review. No criteria changes.
v2.2019	04/03/2019	Laura Rebek, MS, CGC	Semi-annual review. No criteria changes. Updated references.
v1.2019	10/03/2018	Heather Dorsey, MS, CGC	Semi-annual review. Additional criteria for early-onset epilepsy added. Background, professional society guidelines and references updated. Administrative change to genetic counseling requirement - moved from client policy to guidelines. CPT code list reformatted. PMID added.
v1.2018	03/31/2018	Heather Dorsey, MS, CGC	Semi-annual review. No criteria changes. Disclaimer sentence added to scope. Background, professional society guidelines and references updated.
v1.2017	10/27/2017	Heather Dorsey, MS, CGC	Quarterly review. No criteria changes. Updated references.
v1.2017	09/11/2017	Megan Czarniecki, MS, CGC	Formatted references to NLM style. Moved methodological considerations to appropriate use criteria and background. Updated associated CPT codes. Removed genetic counseling recommendation. Approved by Policy Lead.
v1.2017	07/03/2017	Heather Dorsey, MS, CGC	Quarterly review. No criteria changes. Added statement to clarify that WES for carrier screening is not included in coverage criteria. Updated references. Approved by Policy Lead.
v1.2017	04/25/2017	Gwen Fraley, MS, CGC	Quarterly review. No criteria changes. Updated references.
v1.2017	12/20/2016	Heather Dorsey, MS, CGC	Quarterly review. No criteria changes. Updated references and renumbered to 2017.

PROPRIETARY

Guidelines developed by, and used with permission from, Informed Medical Decisions, Inc. © 2015-2022 Informed Medical Decisions, Inc. All Rights Reserved.

v1.2016	10/03/2016	Gwen Fraley, MS, CGC	Added criteria for exome reanalysis. Updated references.
v1.2015	08/27/2015	Gwen Fraley, MS, CGC	Original version

**Original Effective Date:** 08/27/2015

**Primary Author:** Gwen Fraley, MS, CGC

ARCHIVED

PROPRIETARY

Guidelines developed by, and used with permission from, Informed Medical Decisions, Inc. © 2015-2022 Informed Medical Decisions, Inc. All Rights Reserved.